Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin

References

• Islami F, Miller KD, Siegel RL, et al. National and state estimates of lost earnings from cancer deaths in the United States. JAMA Oncol. 2019;5(9):e191460–e191460. doi:10.1001/jamaoncol.2019.1460
   PubMed Web of Science ®Google Scholar
• Lotan Y, Goodman PJ, Youssef RF, et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated Select. J Urol. 2012;187(6):2005–2010. doi:10.1016/j.juro.2012.01.117
   PubMed Web of Science ®Google Scholar
• Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. Hematol Oncol Clin North Am. 1992;6(1):1–30. doi:10.1016/S0889-8588(18)30360-5
   PubMed Web of Science ®Google Scholar
• Miyazaki J, Nishiyama HJ. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24(10):730–734. doi:10.1111/iju.13376
   PubMed Web of Science ®Google Scholar
• Guillaume L, Guy L. [Epidemiology of and risk factors for bladder cancer and for urothelial tumors]. Epidémiologie et facteurs de risque des cancers de la vessie et des tumeurs urothéliales. Rev Prat. 2014;64(10):1372–1374. French.
   PubMedGoogle Scholar
• Rushton L, Hutchings SJ, Fortunato L, et al. Occupational cancer burden in Great Britain. Br J Cancer. 2012;107(Suppl 1):S3. doi:10.1038/bjc.2012.112
   PubMed Web of Science ®Google Scholar
• Ros MM, Bas Bueno-de-Mesquita HB, Büchner FL, et al. Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2011;128(11):2695–2708. doi:10.1002/ijc.25592
   PubMed Web of Science ®Google Scholar
• Rouprêt M, Babjuk M, Compérat E, et al. European Association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol. 2015;68(5):868–879. doi:10.1016/j.eururo.2015.06.044
   PubMed Web of Science ®Google Scholar
• Corral R, Lewinger JP, Van Den Berg D, et al. Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. Int J Cancer. 2014;135(2):335–347. doi:10.1002/ijc.28693
   PubMed Web of Science ®Google Scholar
• Deng C, Guo H, Yan D, Liang T, Ye X, Li Z. Pancancer analysis of neurovascular-related NRP family genes as potential prognostic biomarkers of bladder urothelial carcinoma. Biomed Res Int. 2021;2021:5546612. doi:10.1155/2021/5546612
   PubMed Web of Science ®Google Scholar
• Dyrskjøt L, Reinert T, Algaba F, et al. Prognostic impact of a 12-gene progression score in non–muscle-invasive bladder cancer: a prospective multicentre validation study. Eur Urol. 2017;72(3):461–469. doi:10.1016/j.eururo.2017.05.040
   PubMed Web of Science ®Google Scholar
• Choi W, Ochoa A, McConkey DJ, et al. Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. Eur Urol. 2017;72(3):354–365. doi:10.1016/j.eururo.2017.03.010
   PubMed Web of Science ®Google Scholar
• Packiam VT, Labbate CV, Boorjian SA, et al. The Association of Salvage Intravesical Therapy Following BCG with Pathologic Outcomes and Survival After Radical Cystectomy for Patients with High-Grade Non-Muscle Invasive Bladder Cancer: A Multi-Institution Analysis. Elsevier; 2021.
   Google Scholar
• Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med. 1999;189(9):1451–1460. doi:10.1084/jem.189.9.1451
   PubMed Web of Science ®Google Scholar
• Ludwig AT, Moore JM, Luo Y, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity. Cancer Res. 2004;64(10):3386–3390. doi:10.1158/0008-5472.Can-04-0374
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964–1970. doi:10.1016/s0022-5347(05)64273-5
   PubMed Web of Science ®Google Scholar
• Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004;63(4):682–686. doi:10.1016/j.urology.2003.11.049
   PubMed Web of Science ®Google Scholar
• Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90–95. doi:10.1016/s0022-5347(05)64043-8
   PubMed Web of Science ®Google Scholar
• Waked R, Choucair J, Chehata N, Haddad E, Saliba CT. Intravesical Bacillus Calmette-Guérin (BCG) treatment’s severe complications: a single institution review of incidence, presentation and treatment outcome. J Clin Tuberc Other Mycobact Dis. 2020;19:100149. doi:10.1016/j.jctube.2020.100149
   PubMedGoogle Scholar
• Thyavihally YB, Dev P, Waigankar S, et al. Intravesical bacillus Calmette-Guerin (BCG) in treating non-muscle invasive bladder cancer—analysis of adverse effects and effectiveness of two strains of BCG (Danish 1331 and Moscow-I). Asian J Urol. 2022;9(2):157–164. doi:10.1016/j.ajur.2021.05.002
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu J, Huang Y, Ma LJJo O. Clinical spectrum of complications induced by intravesical immunotherapy of Bacillus Calmette-Guérin for bladder cancer. J Oncol. 2019;2019:1–11. doi:10.1155/2019/6230409
   Web of Science ®Google Scholar
• Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380(8):741–751. doi:10.1056/NEJMoa1814213
   PubMed Web of Science ®Google Scholar
• Syed YY. Sacituzumab govitecan: first approval. Drugs. 2020;80:1019–1025. doi:10.1007/s40265-020-01337-5
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39(22):2474. doi:10.1200/JCO.20.03489
   PubMed Web of Science ®Google Scholar
• Mathew Thomas V, Tripathi N, Agarwal N, Swami U. Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Expert Rev Anticancer Ther. 2022;22(4):335–341. doi:10.1080/14737140.2022.2049763
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Faltas BM, Lam ET, et al. Sacituzumab Govitecan (IMMU-132) in Patients with Previously Treated Metastatic Urothelial Cancer (Muc): Results from a Phase I/II Study. American Society of Clinical Oncology; 2019.
   Google Scholar
• Grivas P, Tagawa ST, Bellmunt J, et al. Tropics-04: Study of Sacituzumab Govitecan in Metastatic or Locally Advanced Unresectable Urothelial Cancer That Has Progressed After Platinum and Checkpoint Inhibitor Therapy. American Society of Clinical Oncology; 2021.
   Google Scholar
• Tagawa ST, Ocean AJ, Lam ET, et al. Therapy for Chemopretreated Metastatic Urothelial Cancer (Muc) with the Antibody-Drug Conjugate (ADC) Sacituzumab Govitecan (IMMU-132). American Society of Clinical Oncology; 2017.
   Google Scholar
• Faltas B, Goldenberg DM, Ocean AJ, et al. Sacituzumab govitecan, a novel antibody–drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016;14(1):e75–e79. doi:10.1016/j.clgc.2015.10.002
   PubMed Web of Science ®Google Scholar
• Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int. 2008;102(9 Pt B):1242–1246. doi:10.1111/j.1464-410X.2008.07966.x
   PubMed Web of Science ®Google Scholar
• Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523–531. doi:10.1016/s0302-2838(02)00068-4
   PubMed Web of Science ®Google Scholar
• Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol. 2010;57(5):843–849. doi:10.1016/j.eururo.2009.05.047
   PubMed Web of Science ®Google Scholar
• Sfakianos JP, Kim PH, Hakimi AA, Herr HW. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. J Urol. 2014;191(2):341–345. doi:10.1016/j.juro.2013.08.022
   PubMed Web of Science ®Google Scholar
• Jäger W, Thomas C, Haag S, et al. Early vs delayed radical cystectomy for ‘high-risk’ carcinoma not invading bladder muscle: delay of cystectomy reduces cancer-specific survival. BJU Int. 2011;108(8 Pt 2):E284–8. doi:10.1111/j.1464-410X.2010.09980.x
   PubMedGoogle Scholar
• Kamat AM, Gee JR, Dinney CP, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006;175(3 Pt 1):881–885. doi:10.1016/s0022-5347(05)00423-4
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN clinical practice guidelines in oncology. Bladder Cancer; 2009.
   Google Scholar
• Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338–348. doi:10.1056/NEJMoa1817323
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015;33(17):1974–1982. doi:10.1200/jco.2014.59.4358
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. doi:10.1056/NEJMoa1613683
   PubMed Web of Science ®Google Scholar
• Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 2017;3(9):e172411. doi:10.1001/jamaoncol.2017.2411
   PubMed Web of Science ®Google Scholar
• Gevaert T, Cimadamore A, Eckstein M, et al. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go. Fut Oncol. 2019;15(19):2199–2202. doi:10.2217/fon-2019-0217
   PubMed Web of Science ®Google Scholar
• Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer modelsADC cancer therapeutic targeting nectin-4. Cancer Res. 2016;76(10):3003–3013. doi:10.1158/0008-5472.CAN-15-1313
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang J, Shen Q, et al. High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett. 2018;15(6):8789–8795. doi:10.3892/ol.2018.8365
   PubMed Web of Science ®Google Scholar
• Rosenberg J, Sridhar SS, Zhang J, et al. EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. 2020;38(10):1041–1049. doi:10.1200/jco.19.02044
   PubMed Web of Science ®Google Scholar
• Evan YY, Petrylak DP, O’Donnell PH, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, Phase 2 trial. Lancet Oncol. 2021;22(6):872–882. doi:10.1016/S1470-2045(21)00094-2
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Rosenberg JE, Duran I, et al. EV-301: Phase III Study to Evaluate Enfortumab Vedotin (EV) versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (la/Muc). American Society of Clinical Oncology; 2019.
   Google Scholar
• Powles T, Rosenberg JE, Sonpavde G, et al. Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma. American Society of Clinical Oncology; 2021.
   Google Scholar
• Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023;41(1):22–31. doi:10.1200/jco.22.01643
   PubMed Web of Science ®Google Scholar
• Takahashi S, Uemura M, Kimura T, et al. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma. Invest New Drugs. 2020;38(4):1056–1066. doi:10.1007/s10637-019-00844-x
   PubMed Web of Science ®Google Scholar
• Van Der Heijden MS, Gupta S, Galsky MD, et al. Study EV-302: a two-arm, open-label, randomized controlled Phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC)(trial in progress). Am Soc Clin Oncol. 2022;40:TPS589–TPS589. doi:10.1200/JCO.2022.40.6_suppl.TPS589
   Google Scholar
• Swami U, Grivas P, Pal SK, Agarwal NJCT; Communications R. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: lessons from real world experience. Cancer Treat Res Commun. 2021;27:100325. doi:10.1016/j.ctarc.2021.100325
   PubMedGoogle Scholar
• Drakaki A, Rezazadeh Kalebasty A, Lee J-L, et al. Phase Ib/II Umbrella Trial to Evaluate the Safety and Efficacy of Multiple 2L Cancer Immunotherapy (CIT) Combinations in Advanced/Metastatic Urothelial Carcinoma (Muc): MORPHEUS-Muc. American Society of Clinical Oncology; 2020.
   Google Scholar